Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (3.744.375 €): Vorbereitung auf RSV-Immunisierung und -überwachung in Europa Hor 28.05.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Vorbereitung auf RSV-Immunisierung und -überwachung in Europa

RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progress has been made in development of products for active and passive immunization against RSV, with 19 products currently in clinical development. In 2017, we were funded by IMI to set up RESCEU project (Grant Agreement number 116019), which is the single largest consortium currently working on RSV and has addressed several of the key evidence gaps to inform the introduction of an RSV vaccine. However, new gaps in evidence have emerged and many key requirements for the introduction of a novel RSV vaccine into national immunisation programmes (not addressed within RESCEU) remain unmet. PROMISE’s vision is to seamlessly build on, exploit, and add value to the significant achievements of RESCEU to prepare for the imminent introduction of an RSV vaccine. Expanding the existing RESCEU network to include 5 new partners, PROMISE comprises of 5 distinct but inter-connected work packages (WPs). WP 1 will conduct epidemiological and cost-effectiveness analyses marshalling data from systematic reviews; national and regional disease registries; surveillance programmes and linked routine healthcare datasets. WP2 will foster a consensus and develop an operational plan for expanded coordinated RSV surveillance and reporting activities; post-licensure monitoring and evaluation of products for RSV immunization across Europe. WP3 will initiate new prospective studies to address key gaps in existing knowledge (RSV disease severity scores, asthma in school age children) and assemble biobanks for biomarker validation. WP4 will validate temporally and at mucosal level biomarkers that were identified in RESCEU adopting state of the art technologies. WPs 1-4 will develop high-quality, sustainable, robust data collection systems that link closely with public health/regulatory bodies/health care providers for informing policy and regulatory processes.


Geförderte Unternehmen:

Firmenname Förderungssumme
Astrazeneca AB 0,00 €
Fondazione Penta ETS 53.750 €
Fundacion para El Fomento de La Investigacion Sanitaria y Biomedica de La Comunitat Valenciana 67.500 €
Glaxosmithkline Biologicals SA 0,00 €
Imperial College of Science Technology and Medicine 305.000 €
Janssen Pharmaceutica N.V. 0,00 €
Martin-Luther-Universitat Halle-Wittenberg 98.750 €
Novavax Inc. 0,00 €
Pfizer Ltd. 0,00 €
Rijksinstituut Voor Volksgezondheid EN Milieu (Rivm) 358.125 €
Sanofi R&D Vaccins 0,00 €
Servizo Galego de Saude 67.500 €
Statens Serum Institut 150.000 €
Stichting Nederlands Instituut Voor Onderzoek Van DE Gezondheidszorg 129.375 €
Stichting Resvinet 84.375 €
Teamit Research SL 587.125 €
Terveyden JA Hyvinvoinnin Laitos 170.625 €
The Chancellor, Masters and Scholars of the University of Oxford 203.750 €
The University of Edinburgh 746.625 €
Universitair Medisch Centrum Utrecht 470.000 €
Universiteit Antwerpen 95.000 €
Varsinais-Suomen Hyvinvointialue 126.915 €
Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma 29.960 €

Quelle: https://cordis.europa.eu/project/id/101034339

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.